Analysis of 307 cases with drug‐induced liver injury between 2010 and 2018 in Japan

• DOI: 10.1111/hepr.13288
• Publication Date: 2018-12-19T15:09:28Z
• Authors: Mitsuhiko Aiso; Hajime Takikawa; Keiji Tsuji; Tatehiro Kagawa; Masaaki Watanabe; Atsushi Tanaka; Ken Sato; Shotaro Sakisaka; Yoichi Hiasa; Yoshiyuki Takei; Hiromasa Ohira; Minoru Ayada; Etsuko Hashimoto; Shuichi Kaneko; Yoshiyuki Ueno; Kenji Ohmoto; Akinobu Takaki; Takuji Torimura; Yasushi Matsuzaki; Kazuto Tajiri; Masashi Yoneda; Takayoshi Ito; Naoya Kato; Kenichi Ikejima; Satoshi Mochida; Hiroshi Yasuda; Naoya Sakamoto
• Keywords: Liver disease; Alanine aminotransferase

In order to know the present status of drug-induced liver injury (DILI) in Japan, we data prospectively collected DILI cases between 2010 and 2018 from 27 hospitals.Drug-induced diagnosed by experts hospitals all over Japan have been since 2010. Alanine aminotransferase level ≥150 U/L and/or alkaline phosphatase ≥2× upper limit normal were inclusion criteria.In total, 307 (125 male 182 female individuals) aged 17 86 years old collected. The types as follows: 64% hepatocellular type, 20% mixed 16% cholestatic type. A lymphocyte stimulation test was carried out 59% cases, positive 48% semipositive 3% cases. Eosinophilia ≥6% observed 27% Fifty-three percent occurred within 30 days 79% 90 after starting drug administration. By diagnostic scale Digestive Disease Week (DDW)-Japan 2004 workshop, 93.8% "highly probable", 5.9% "possible".Japanese patients are somewhat different those Europe North America. DDW-Japan workshop has used Japan. However, there many issues improve causality assessment that must investigate future. It is critical elucidate mechanisms metabolism pathophysiology various drugs prevent DILI.